Cost-effectiveness of empagliflozin compared with liraglutide based on cardiovascular outcome trials in Type II diabetes.
Conclusion: Results suggest that empagliflozin+SoC is cost effective versus SoC and liraglutide+SoC.
PMID: 32573253 [PubMed - as supplied by publisher]
Source: Journal of Comparative Effectiveness Research - Category: General Medicine Tags: J Comp Eff Res Source Type: research
More News: Cardiology | Cardiovascular | Diabetes | Empagliflozin | Endocrinology | General Medicine | Heart | Jardiance | Victoza